secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syros Pharmaceuticals, Inc. (—)
CIK:        0001556263
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001193125-25-042498
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 3.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syros Pharmaceuticals to voluntarily delist from Nasdaq; CEO Quirk steps down, wind-down underway
--------------------------------------------------------------------------------

- Voluntary delisting from Nasdaq; Form 25 to be filed ~March 10, 2025, effective ~March 20; intends to file Form 15 to suspend SEC reporting.
- CEO Gerald Quirk steps down as CEO/President effective March 1; remains on Board as director and consultant.
- Directors Peter Wirth, Marsha Fanucci, Nancy Simonian resign from Board effective immediately; no disagreement.
- Matthew Foster appointed Chief Restructuring Officer effective March 1 to oversee wind-down.
- Wind-down triggered by Phase 3 trial (SELECT-MDS-1) failure and default under Oxford Finance loan; operating under Oxford-approved budget.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/d926755d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-042498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer